Thiazolidinedione

Summary

Thiazolidinedione (CHEMBL85398) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including diabetes mellitus and coronary artery disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 11
• Chemistry: 117.13 Da · C3H3NO2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL85398
Name	Thiazolidinedione
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5437
ChEBI	CHEBI:50992
Molecular formula	C3H3NO2S
Molecular weight	117.13
InChIKey	ZOBPZXTWZATXDG-UHFFFAOYSA-N

SMILES: C1C(=O)NC(=O)S1

IUPAC name: 1,3-thiazolidine-2,4-dione

ChEBI definition: A thiazolidenedione carrying oxo substituents at positions 2 and 4.

Also known as: NSC-6745, Thiazolidinedione, THIAZOLIDINEDIONE

Patent coverage: 15,853 distinct patent families (54,290 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 54,117 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Glycogen synthase kinase-3, Alpha glucosidase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MGAM	6.27	IC50	540	nM	CHEMBL_ACT_18850477

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	3	MONDO:0005015	EFO:0000400
coronary artery disorder	3	MONDO:0005010	EFO:0001645
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
type 1 diabetes mellitus	1	MONDO:0005147	MONDO:0005147

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	7
PHASE1	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00046462	PHASE3	COMPLETED	Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
NCT00396227	PHASE3	COMPLETED	Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone
NCT00683878	PHASE3	COMPLETED	Add-on to Thiazolidinedione (TZD) Failures
NCT00975286	PHASE3	COMPLETED	24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
NCT01468181	PHASE3	COMPLETED	A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
NCT01777282	PHASE3	COMPLETED	A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
NCT07057479	PHASE3	WITHDRAWN	Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
NCT00214253	PHASE1	COMPLETED	Islet Transplantation in Type 1 Diabetic Patients
NCT00285844	PHASE1	COMPLETED	Integrating the Genetic and Metabolic Faces of Obesity
NCT06838286	Not specified	RECRUITING	Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
NCT03249506	Not specified	COMPLETED	Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).